These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17661403)

  • 1. Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis.
    Caldwell SH; Argo CK
    Hepatology; 2007 Aug; 46(2):285-7. PubMed ID: 17661403
    [No Abstract]   [Full Text] [Related]  

  • 2. NASH and thiazolidinediones: not to be taken lightly.
    Dufour JF
    J Hepatol; 2007 Oct; 47(4):451-3. PubMed ID: 17692990
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
    García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
    Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.
    Park SJ; Lee YC
    J Asthma; 2008; 45(1):1-8. PubMed ID: 18259989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
    Zieleniak A; Wójcik M; Woźniak LA
    Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
    Akahori T; Sho M; Hamada K; Suzaki Y; Kuzumoto Y; Nomi T; Nakamura S; Enomoto K; Kanehiro H; Nakajima Y
    J Hepatol; 2007 Dec; 47(6):784-92. PubMed ID: 17936399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
    Inamoto T; Shah JB; Kamat AM
    Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
    Lutchman G; Modi A; Kleiner DE; Promrat K; Heller T; Ghany M; Borg B; Loomba R; Liang TJ; Premkumar A; Hoofnagle JH
    Hepatology; 2007 Aug; 46(2):424-9. PubMed ID: 17559148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effects of glycine on the expression of peroxisome-proliferator-activated receptor gamma in nonalcoholic fatty rat livers].
    Liu JC; Guo YR; Chai B
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):702-3. PubMed ID: 18822216
    [No Abstract]   [Full Text] [Related]  

  • 19. Glitazones in the treatment of cardiovascular risk factors.
    Bouhlel MA; Chinetti-Gbaguidi G; Staels B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():7-13. PubMed ID: 18001313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.